GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (NAS:GRFS) » Definitions » ROE % Adjusted to Book Value

Grifols (Grifols) ROE % Adjusted to Book Value

: 4.15% (As of Sep. 2023)
View and export this data going back to 2011. Start your Free Trial

Grifols's ROE % for the quarter that ended in Sep. 2023 was 3.94%. Grifols's PB Ratio for the quarter that ended in Sep. 2023 was 0.95. Grifols's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 was 4.15%.


Grifols ROE % Adjusted to Book Value Historical Data

The historical data trend for Grifols's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.60 6.40 2.80 3.90 0.81

Grifols Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
ROE % Adjusted to Book Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.47 4.13 4.15 3.07

Competitive Comparison

For the Drug Manufacturers - General subindustry, Grifols's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grifols ROE % Adjusted to Book Value Distribution

For the Drug Manufacturers industry and Healthcare sector, Grifols's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Grifols's ROE % Adjusted to Book Value falls into.



Grifols ROE % Adjusted to Book Value Calculation

Grifols's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=1.00% / 1.23
=0.81%

Grifols's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=3.94% / 0.95
=4.15%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Grifols ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Grifols's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Grifols (Grifols) Business Description

Industry
Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.

Grifols (Grifols) Headlines

From GuruFocus